featured
First Biosimilar Approved to Treat Multiple Sclerosis
Tyruko, biosimilar to Tysabri (natalizumab) injection, approved for treatment of clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.